Drug Resistance Updates
Volume 9, Issue 1 , Pages 26-39 , February 2006

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use

  • F. Javier Pérez-Victoria

      Affiliations

    • Instituto de Parasitología y Biomedicina “López-Neyra”, Spanish Research Council (C.S.I.C.), Granada, Spain
    • ,
  • María P. Sánchez-Cañete

      Affiliations

    • Instituto de Parasitología y Biomedicina “López-Neyra”, Spanish Research Council (C.S.I.C.), Granada, Spain
    • ,
  • Karin Seifert

      Affiliations

    • Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    • ,
  • Simon L. Croft

      Affiliations

    • Drugs for Neglected Diseases Initiative, Geneva, Switzerland
    • ,
  • Shyam Sundar

      Affiliations

    • Kala-azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    • ,
  • Santiago Castanys

      Affiliations

    • Instituto de Parasitología y Biomedicina “López-Neyra”, Spanish Research Council (C.S.I.C.), Granada, Spain
    • The authors are equal senior investigators in this study.
    • ,
  • Francisco Gamarro

      Affiliations

    • Instituto de Parasitología y Biomedicina “López-Neyra”, Spanish Research Council (C.S.I.C.), Granada, Spain
    • The authors are equal senior investigators in this study.
    • Corresponding Author InformationCorresponding author at: Instituto de Parasitología y Biomedicina “López-Neyra”. C.S.I.C. Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento s/n, 18100 Armilla, Granada, Spain. Tel.: +34 958181667; fax: +34 958181632.

Received 5 November 2005 ,Revised 27 March 2006 ,Accepted 6 April 2006.

References 

  1. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 2005;3:547–556
  2. Araujo-Santos JM, Parodi-Talice A, Castanys S, Gamarro F. The overexpression of an intracellular ABCA-like transporter alters phospholipid trafficking in Leishmania. Biochem. Biophys. Res. Commun. 2005;330:349–355
  3. Arthur G, Bittman R. The inhibition of cell signalling pathways by antitumor ether-lipids. Biochim. Biophys. Acta. 1998;1390:85–102
  4. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. 2004;38:217–221
  5. Beach DH, Holz , Anekwe GE. Lipids of Leishmania promastigotes. J. Parasitol. 1979;65:201–216
  6. Beach DH, Goad LJ, Holz GG. Effects of antimytotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol. Biochem. Parasitol. 1988;31:149–162
  7. Beckers T, Voegeli R, Hilgard P. Molecular and cellular effects of hexadecylphosphocholine (miltefosine) in human myeloid leukaemia cell lines. Eur. J. Cancer. 1994;30A:2143–2150
  8. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002;71:537–592
  9. Brachwitz H, Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharm. Ther. 1995;66:39–82
  10. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health. 2001;6:928–934
  11. Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 1998;18:219–224
  12. Burk K, David M, Junge K, Sindermann H. Overview on the clinical development of miltefosine solution (Miltex) for the treatment of cutaneous breast cancer. Drugs Today. 1994;30:59–72
  13. Callaghan R, van Gorkom LC, Epand RM. A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. Br. J. Cancer. 1992;66:781–786
  14. Chunge CN, Gachihi G, Muigai R, Wasunna K, Rashid JR, Chulay JD, et al. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Trop. Med. Hyg. 1985;79:715–718
  15. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 1990;84:221–225
  16. Croft SL. Drug Resistance in Leishmaniasis. World Health Organization; 2004;pp. 108–119
  17. Croft SL, Barrett M, Urbina JA. Chemotherapy of trypanosomiasis and leishmaniasis. Trends Parasitol. 2005;21:508–512
  18. Croft SL, Coombs GH. Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19:502–508
  19. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkylphosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 1987;36:263–2636
  20. Cuenca-Estrella M. Combinations of antifungal agents in therapy—what value are they?. J. Antimicrob. Chemother. 2004;54:854–869
  21. Cupolillo E, Medina-Acosta E, Noyes H, Momen H, Grimaldi G. A revised classification for Leishmania and Endotrypanum. Parasitol. Today. 2000;16:142–144
  22. Dube A, Singh N, Sundar S. Refractoriness to the treament of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol. Res. 2005;96:216–223
  23. Ellard GA. Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs. Int. J. Lepr. Other Mycobact. Dis. 1984;52:395–401
  24. Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 2002;81:151–157
  25. Gajate C, Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab. 2002;3:491–525
  26. Ganguly, N.K., 2002. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News, World Health Organisation, vol. 68, p. 2.
  27. Goad L, Holz GG, Beach DH. Sterols of Leishmania species. Implication for biosynthesis. Mol. Biochem. Parasitol. 1984;10:161–170
  28. Grant AM, Hanson PK, Malone L, Nichols JW. NBD-labeled phosphatidylcholine and phosphatidylethanolamine are internalized by transbilayer transport across the yeast plasma membrane. Traffic. 2001;2:37–50
  29. Grogl T, Thomason N, Franke ED. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 1992;47:117–126
  30. Gupta S, Ramesh SC, Srivastava VM. Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. Acta Trop. 2005;94:47
  31. Hanson PK, Malone L, Birchmore JL, Nichols JW. Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J. Biol. Chem. 2003;278:36041–36050
  32. Hilgard P, Kampherm E, Nolan L, Pohl J, Reissmann T. Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J. Cancer Res. Clin. Oncol. 1991;117:403–408
  33. Hoffmann J, Utz I, Spitaler M, Hofe S, Rybczynska M, Beck WT, et al. Resistance to the new anti-cancer phospholipid ilmofosine (BM41 440). Br. J. Cancer. 1997;76:862–869
  34. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 1999;341:1795–1800
  35. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob. Agents Chemother. 2004;48:693–715
  36. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 1992;36:1630–1634
  37. Legare D, Richard D, Mukhopadhyay R, Stierhof YD, Rosen BP, Haimeur A, et al. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. 2001;276:26301–26307
  38. Lira R, Contreras LM, Rita RM, Urbina JA. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 2001;47:537–546
  39. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, et al. Evidence that the high incidente of treatment failures in Indian kala-azar is due to the emergente of antimony resistant strains of Leishmania donovani. J. Infect. Dis. 1999;180:564–567
  40. Lux H, Heise N, Klenner T, Hart D, Opperdoes FR. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 2000;111:1–14
  41. McConville MJ, Mullin KA, Ilgoutz SC, Teasdale RD. Secretory pathway of trypanosomatid parasites. Microbiol. Mol. Biol Rev. 2002;66:122–154
  42. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 2000;181:795–799
  43. Murray HW, Hariprashad J. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 1996;40:586–587
  44. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 1995;35:577–584
  45. Paris C, Loiseau PM, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 2004;48:852–859
  46. Parodi-Talice A, Araujo JM, Torres C, Pérez-Victoria JM, Gamarro F, Castanys S. The overexpression of a new ABC transporter in Leishmania is related to phospholipid trafficking and reduced infectivity. Biochim. Biophys. Acta. 2003;1612(2):195–207
  47. Pérez-Victoria FJ, Castanys S, Gamarro F. Resistance to miltefosine in Leishmania donovani involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 2003;47:2397–2403
  48. Pérez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter: a novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 2003;278:49965–49971
  49. Perez-Victoria JM, Pérez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, Castanys S, et al. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 2001;45:2468–2474
  50. Pomorski T, Lombardi R, Riezman H, Devaux PF, van Meer G, Holthuis JC. Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis. Mol. Biol. Cell. 2003;14:1240–1254
  51. Pomorski T, Holthuis JCM, Herrmann A, van Meer G. Tracking down lipid flippases and their biological functions. J. Cell Sci. 2004;117:805–813
  52. Quispe-Tintaya KW, Laurent T, Decuypere S, Hide M, Banuls AL, De Doncker S, et al. Fluorogenic assay for molecular typing of the Leishmania donovani complex: taxonomic and clinical applications. J. Infect. Dis. 2005;192:685–692
  53. Raggers RJ, Pomorski T, Holthuis JC, Kalin N, van Meer G. Lipid traffic: the ABC of transbilayer movement. Traffic. 2000;1:226–234
  54. Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug–membrane interactions. Antimicrob. Agents Chemother. 2005;49:2677–2686
  55. Rybczynska M, Liu R, Lu P, Sharom FJ, Steinfels E, Pietro AD, et al. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer. 2001;84:1405–1411
  56. Rybczynska M, Spitaler M, Knebel NG, Boeck G, Grunicke H, Hofmann J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 2001;62:765–772
  57. Santa-Rita RM, Santos Barbosa H, Meirelles MN, de Castro SL. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 2000;75:219–228
  58. Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin. Infect. Dis. 2005;40:120–124
  59. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 1993;168:715–720
  60. Seifert K, Matu S, Pérez-Victoria FJ, Castanys S, Gamarro F, Croft SL. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents. 2003;22:380–387
  61. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other anti-leishmanial drugs. Antimicrob. Agents Chemother. 2006;50:73–79
  62. Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. 2004;39:1520–1523
  63. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 2004;38:1266–1272
  64. Soto J, Toledo J, Soto J, Toledo J, Gutierrez P, Nicholls RS, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 2001;33:57–61
  65. Storme GA, Berdel WE, van Blittterswijk WJ, Bruyneel EA, De Bruyne GK, Marcel MM. Antiinvasive effect of racemic 1-O-octadecyl-2-O-methlglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res. 1985;45:351–357
  66. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health. 2001;6:654–849
  67. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. J. 2003;22:434–438
  68. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 2002;347:1739–1746
  69. Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 2000;31:1110–1113
  70. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 2000;31:1104–1107
  71. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull. World Health Organ. 2005;83:394–395
  72. Tang X, Halleck MS, Schlegel RA, Williamson P. A subfamily of P-type ATPases with aminophospholipid transporting activity. Science. 1996;272:1495–1497
  73. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 2000;94:429–431
  74. van der Sanden MH, Houweling M, Duijsings D, Vaandrager AB, van Golde LM. Inhibition of phosphatidycholine sinthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis. Biochim. Biophys. Acta. 2004;1636:99–107
  75. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996;87:507–517
  76. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother. 2004;48:3010–3015
  77. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 1999;41:301–308
  78. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 2005;73:272–275
  79. Zeisig R, Rudolf M, Eue I, Arndt D. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J. Cancer Res. Clin. Oncol. 1995;121:69–75
  80. Zoeller RA, Layne MD, Modest EJ. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res. 1995;36:1866–1875

PII: S1368-7646(06)00021-5

doi: 10.1016/j.drup.2006.04.001

Drug Resistance Updates
Volume 9, Issue 1 , Pages 26-39 , February 2006

Article Tools

* Image Usage & Resolution